Medtronic is exercising its option to acquire Cathworks for up to $585 million, incorporating the company’s angiography‑derived physiology and coronary assessment technology into Medtronic’s interventional portfolio. The acquisition follows Medtronic’s prior strategic investments and aligns with its push to broaden image‑guided and physiology‑driven solutions for coronary disease. Medtronic cited the deal as a way to accelerate clinical adoption of non‑wire coronary assessment tools and integrate Cathworks’ software into its procedural ecosystem; the transaction underscores ongoing consolidation in the interventional cardiology tools market.